For example, Cluster 1 includes the CD34+ oncoprotein-negative control sample as well as 8 AML samples, 2 infant ALLs, 1 mixed phenotype acute leukemia (MPAL), and an AML that resulted from a lineage-switching event that occurred during treatment with the menin inhibitor. This evidence concerns the gene MEN1 and acute myeloid leukemia.